Comparison
While Thymosin Beta-4 promotes wound healing, angiogenesis, and tissue regeneration in preclinical models via effects on cytoskeleton dynamics, cell migration, and anti-apoptotic pathways25579, Tirzepatide is approved for type 2 diabetes and obesity, producing larger HbA1c and body-weight reductions than semaglutide in head-to-head trials24.
While Thymosin Beta-4 works as an endogenous 43-amino-acid actin-sequestering peptide that maintains a pool of G-actin monomers and regulates actin polymerization, thereby influencing cell migration, proliferation, and differentiation25579, Tirzepatide is a 39-amino-acid synthetic peptide primarily based on GIP sequence with C20 fatty diacid conjugation that acts as a dual agonist at GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite24.
Thymosin Beta-4 is 43 amino acids long, whereas Tirzepatide is shorter as it has a length of 39 amino acids. Thymosin Beta-4 is made up of a sequence of Serine, Aspartic acid, Lysine, Proline, Aspartic acid, Methionine, Alanine, Glutamic acid, Isoleucine, Glutamic acid, Lysine, Phenylalanine, Aspartic acid, Lysine, Serine, Lysine, Lysine, Proline, Aspartic acid, Methionine, Alanine, Glutamic acid, Glutamic acid, Lysine, Phenylalanine, Aspartic acid, Lysine, Lysine, Glutamic acid, Lysine, Lysine, Glutamic acid, Glutamic acid, Alanine, Glutamic acid, Asparagine, Glutamic acid, Glutamic acid, Lysine, Glutamic acid, Serine. Tirzepatide is made up of a sequence of sequence data not available in the current dataset.
Thymosin Beta-4
TMSB4X
Tirzepatide
Not assigned in the current dataset.